|
Jun 26
|
Devonian Health Group Reports Third Quarter 2025 Financial Results
|
|
Feb 19
|
Devonian Announces the Filing of a New Patent Application Relating to the Use of Thykamine™ as an Antifibrotic Agent
|
|
Feb 18
|
Devonian Announces Positive in Vivo Results of Thykamine™ on Gene Expression Associated With Fibrosis
|
|
Dec 24
|
Devonian Health Group First Quarter 2024 Earnings: CA$0.005 loss per share (vs CA$0.009 loss in 1Q 2023)
|
|
Dec 4
|
Devonian Bolsters Leadership Team and Aligns Strategy to Accelerate Clinical Development and Drive Revenue Growth and Commercial Success
|